NCT04237623View on ClinicalTrials.gov

GM-CSF With Post-Transplant Cyclophosphamide

PHASE2RecruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

May 18, 2020

Primary Completion Date

September 18, 2025

Study Completion Date

September 18, 2025

Conditions
Transplant-Related Hematologic Malignancy
Interventions
DRUG

Sargramostim

250mcg/m2/day IV starting Day +5

OTHER

Control Arm

Standard G-CSF given to those who decline to receive GM-CSF

Trial Locations (1)

30342

RECRUITING

Northside Hospital, Atlanta

All Listed Sponsors
lead

Northside Hospital, Inc.

OTHER